Episode Details
Back to Episodes
BIO International 2025: UroGen CEO Liz Barrett discusses last week's approval of ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
Published 1 year, 2 months ago
Description
She describes the unmet need for a new therapy in this setting, and compares and contrasts ZUSDURI to going through multiple transurethral resection of bladder tumor (TURBT) surgeries. Plus, the potential addressable market, and what she believes the approval means for UroGen as a company.